We are live on ! Find out more
KPRX icon

Kiora Pharmaceuticals
KPRX

17 hedge funds and large institutions have $13.7M invested in Kiora Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

6% more funds holding

Funds holding: 16 → 17 (+1)

0% less ownership

Funds ownership: 0.15% → 0.15% (-0%)

28% less capital invested

Capital invested by funds: $19M → $13.7M (-$5.27M)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$364K
2
Citadel Advisors
Citadel Advisors
Florida
+$4.66K
3
NFSG
Newbridge Financial Services Group
Florida
+$4.66K
4
PHP
Parkman Healthcare Partners
Connecticut
+$1.55K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$242K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$115K
3
Two Sigma Investments
Two Sigma Investments
New York
-$112K
4
ECM
ExodusPoint Capital Management
New York
-$62K
5
BlackRock
BlackRock
New York
-$23.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$12.2M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$465K +$364K +234 +193%
Renaissance Technologies
3
Renaissance Technologies
New York
$328K -$242K -156 -38%
PHP
4
Parkman Healthcare Partners
Connecticut
$275K +$1.55K +1 +0.5%
Two Sigma Advisers
5
Two Sigma Advisers
New York
$139K -$115K -74 -41%
Two Sigma Investments
6
Two Sigma Investments
New York
$99K -$112K -72 -49%
Citadel Advisors
7
Citadel Advisors
Florida
$77K +$4.66K +3 +5%
BlackRock
8
BlackRock
New York
$76K -$23.3K -15 -21%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$53K – – –
US Bancorp
10
US Bancorp
Minnesota
$10K – – –
Royal Bank of Canada
11
Royal Bank of Canada
Ontario, Canada
$6K – – –
SFP
12
Sterling Financial Planning
New Jersey
$4K – – –
NFSG
13
Newbridge Financial Services Group
Florida
$4K +$4.66K +3 New
Morgan Stanley
14
Morgan Stanley
New York
$2K – – –
Osaic Holdings
15
Osaic Holdings
Arizona
$2K – – –
UBS Group
16
UBS Group
Switzerland
$1K -$17.1K -11 -92%
AFG
17
Albion Financial Group
Utah
$1K +$1.55K +1 New
ECM
18
ExodusPoint Capital Management
New York
– -$62K -35 Closed

KPRX Hedge Fund Activity: Q2 2021 in Review

17 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q2 2021, worth a combined $13.7M — down 28% from $19M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new KPRX positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 5 trimmed.

The largest buyer was Vanguard Group, adding an estimated $364K. The largest seller was Renaissance Technologies, cutting an estimated $242K.

  • 17 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q2 2021, up from 16 in Q1 2021.
  • Funds reported $13.7M of Kiora Pharmaceuticals stock for Q2 2021, down 28% quarter-over-quarter.
  • 2 funds opened new Kiora Pharmaceuticals positions in Q2 2021 and 1 closed out, a net change of +1 holder.
  • The largest Kiora Pharmaceuticals buyer in Q2 2021 was Vanguard Group, an estimated $364K added.
  • The largest Kiora Pharmaceuticals seller in Q2 2021 was Renaissance Technologies, an estimated $242K sold.

Based on aggregated 13F filings for Q2 2021.